Roche to increase its payroll in Switzerland by 0.75%

Basel, 12 December 2017

Roche is increasing the payroll for its workforce of around 14,000 employees in Switzerland by 0.75% with effect from 1 April 2018. This latest increase acknowledges the great commitment of our employees, taking into account the company's positive performance in a challenging market environment in Europe and Switzerland. The increase also reflects the development of the cost of living.

Over the last few weeks, the Roche Employees Association (AVR) and the Roche Basel Works Council (AKR) held discussions at Roche regarding the adjustment of the 2018 payroll. Unfortunately, an agreement with the two associations could not be reached during the negotiations. The involved parties emphasize that the negotiations took place in a spirit of commitment, fairness and constructiveness.

The 0.75% payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2018.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society.

The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.